Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Goal-directed Hemodynamic Therapy in Radical Cystectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03505112
Recruitment Status : Not yet recruiting
First Posted : April 23, 2018
Last Update Posted : September 6, 2018
Sponsor:
Information provided by (Responsible Party):
Jin-Tae Kim, Seoul National University Hospital

Brief Summary:
Goal-directed therapy (GDT) has been applied to various clinical settings and has been widely researched recently as a method for perioperative management of patients. Radical cystectomy is a complex surgical procedure in which the bladder is removed, followed by urinary diversion. It is an extensive and time-consuming intervention and has high probability of fluid imbalance and bleeding during surgery. We hypothesized that the application of GDT in these patients would improve clinical postoperative outcomes. Therefore, we will attempt to evaluate improvement of postoperative outcomes after applying GDT protocol based on changes in stroke volume index, cardiac index and mean arterial pressure in radical cystectomy.

Condition or disease Intervention/treatment Phase
Bladder Cancer Radical Cystectomy Other: Goal-directed therapy Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 82 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Prospective, single-center, double-blind, parallel-group, randomized, controlled trial
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Effect of Goal-directed Hemodynamic Therapy on Clinical Outcomes in Patients Undergoing Radical Cystectomy: : A Randomized Controlled Trial
Estimated Study Start Date : April 2019
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : June 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Goal-directed therapy group
The patients in goal-directed therapy (GDT) group will be managed according to the goal-directed therapy protocol during the surgery.
Other: Goal-directed therapy

The patients in GDT group will receive intravenous crystalloid fluid or vasopressor or inotropic agent according to the goal-directed therapy protocol utilizing FloTrac / EV1000 clinical platform (Edwards Lifesciences, Irvine, CA, USA).

After induction of anesthesia, the baseline stroke volume index (SVI) is measured and then 200-250 ml of crystalloid is administered over 5-10 minutes. If SVI increase by ≥10%, 200-250 ml of crystalloid is given repeatedly until the increase in SVI <10%. If SVI does not increase by ≥10% and there is no decrease in mean arterial pressure (MAP), revaluate SVI every 10 minutes. Despite an increase in SVI of <10% after fluid challenge, if a decrease in MAP is accompanied by cardiac index (CI) ≤ 2.5 L/min/m2, dobutamine is administered by continuous infusion. If there is a decrease in MAP but no decrease in CI, start low dose norepinephrine continuous infusion.

Other Name: GDT

No Intervention: Control group
The patients in control group will be managed according to standard perioperative care.



Primary Outcome Measures :
  1. A composite of postoperative complications [ Time Frame: through the hospitalization period, an average of 2 weeks ]
    Total incidence of postoperative complications including gastrointestinal complications, complications of infections, wound complications, cardiac events, thromboembolic complications, genitourinary complications, neurological complications based on the Clavien-Dindo classification for radical cystectomy.


Secondary Outcome Measures :
  1. The incidence of postoperative gastrointestinal complications [ Time Frame: through the hospitalization period, an average of 2 weeks ]
    Gastrointestinal complications include ileus, constipation, gastric ulcer, anastomic bowel leak according to the Clavien-Dindo classification for radical cystectomy.

  2. The incidence of postoperative complications of infections [ Time Frame: through the hospitalization period, an average of 2 weeks ]
    Complications of infections include urinary tract infection, sepsis, pneumonia, wound infection according to the Clavien-Dindo classification for radical cystectomy.

  3. The incidence of postoperative wound complications [ Time Frame: through the hospitalization period, an average of 2 weeks ]
    Wound Complications mean wound dehiscence diagnosed clinically and requiring resuturing, according to the Clavien-Dindo classification for radical cystectomy.

  4. The incidence of postoperative cardiac events [ Time Frame: through the hospitalization period, an average of 2 weeks ]
    Cardiac events include myocardial infarction, arrhythmia, congestive heart failure, pulmonary edema and transient brain natriuretic peptide increase (serum brain natriuretic peptide values 100-500 pg/ml) according to the Clavien-Dindo classification for radical cystectomy.

  5. The incidence of postoperative thromboembolic complications [ Time Frame: through the hospitalization period, an average of 2 weeks ]
    Thromboembolic complication means pulmonary embolism evidenced by spiral computerized tomography scanning according to the Clavien-Dindo classification for radical cystectomy.

  6. The incidence of postoperative genitourinary complications [ Time Frame: through the hospitalization period, an average of 2 weeks ]
    Genitourinary complications include renal dysfunction, renal failure, urinary leakage according to the Clavien-Dindo classification for radical cystectomy.

  7. The incidence of postoperative neurological complications [ Time Frame: through the hospitalization period, an average of 2 weeks ]
    Neurological complications mean presence of a de novo focal deficit, confusion/delirium according to the Clavien-Dindo classification for radical cystectomy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients undergoing open radical cystectomy
  • Patients with American Society of Anesthesiologists physical status I-III

Exclusion Criteria:

  • Significant hepatic dysfunction, significant renal dysfunction (estimated glomerular filtration rate <60 ml/min)
  • Congestive heart failure (New York Heart Association scores ≥3), Left Ventricular Ejection Fraction < 35%
  • Arrhythmia
  • Coagulopathy (PT INR >1.5)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03505112


Contacts
Layout table for location contacts
Contact: Jin-Tae Kim, MD, PhD 82-02-2072-2467 jintae73@gmail.com
Contact: Min Hur, MD 82-02-2072-2365 nuage1220@gmail.com

Sponsors and Collaborators
Seoul National University Hospital

Publications:
Layout table for additonal information
Responsible Party: Jin-Tae Kim, Professor, Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT03505112     History of Changes
Other Study ID Numbers: 1712-125-909
First Posted: April 23, 2018    Key Record Dates
Last Update Posted: September 6, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Jin-Tae Kim, Seoul National University Hospital:
Goal-directed therapy
stroke volume index

Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases